AR079352A1 - Anticuerpos neutralizadores contra el receptor de prolactina y su uso terapeutico - Google Patents

Anticuerpos neutralizadores contra el receptor de prolactina y su uso terapeutico

Info

Publication number
AR079352A1
AR079352A1 ARP100104567A ARP100104567A AR079352A1 AR 079352 A1 AR079352 A1 AR 079352A1 AR P100104567 A ARP100104567 A AR P100104567A AR P100104567 A ARP100104567 A AR P100104567A AR 079352 A1 AR079352 A1 AR 079352A1
Authority
AR
Argentina
Prior art keywords
prolactin receptor
benign
antibodies against
therapeutic use
neutralizing antibodies
Prior art date
Application number
ARP100104567A
Other languages
English (en)
Inventor
Christiane Otto
Siegmund Wolf
Christoph Freiberg
Axel Harrenga
Mark Trautwein
Sandra Bruder
Simone Greven
Andrea Eicker
Andreas Wilmen
Original Assignee
Bayer Schering Pharma Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42091520&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR079352(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Schering Pharma Ag filed Critical Bayer Schering Pharma Ag
Publication of AR079352A1 publication Critical patent/AR079352A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/14—Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A61P5/08—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH for decreasing, blocking or antagonising the activity of the anterior pituitary hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2869—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against hormone receptors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Abstract

El anticuerpo neutralizador contra el receptor de prolactina 005-C04, formas maduras de éste y fragmentos de union al antígeno de éste. Composiciones farmacéuticas que los contienen. Su uso en el tratamiento o la prevencion de trastornos e indicaciones benignos mediados por el receptor de prolactina, tales como la endometriosis, la adenomiosis, la anticoncepcion femenina no hormonal, la enfermedad mamaria benigna y la mastalgia, la inhibicion de la lactancia, la hiperpiasia prostática benigna, los fibroides, la pérdida de cabello hiper y normoprolactinémica, y como tratamiento concurrente en una terapia hormonal combinada, con el fin de inhibir la proliferacion de las células del epitelio mamario. Los anticuerpos de solicitud bloquean la senalizacion mediada por el receptor de prolactina.
ARP100104567A 2009-12-10 2010-12-10 Anticuerpos neutralizadores contra el receptor de prolactina y su uso terapeutico AR079352A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP09075546A EP2332995A1 (en) 2009-12-10 2009-12-10 Neutralizing prolactin receptor antibodies and their therapeutic use

Publications (1)

Publication Number Publication Date
AR079352A1 true AR079352A1 (es) 2012-01-18

Family

ID=42091520

Family Applications (6)

Application Number Title Priority Date Filing Date
ARP100104563A AR079348A1 (es) 2009-12-10 2010-12-10 Anticuerpos neutralizadores contra el receptor de prolactina y su uso terapeutico
ARP100104566A AR079351A1 (es) 2009-12-10 2010-12-10 Anticuerpos neutralizadores contra el receptor de prolactina y su uso terapeutico
ARP100104565A AR079350A1 (es) 2009-12-10 2010-12-10 Anticuerpos neutralizadores contra el receptor de prolactina y su uso terapeutico
ARP100104567A AR079352A1 (es) 2009-12-10 2010-12-10 Anticuerpos neutralizadores contra el receptor de prolactina y su uso terapeutico
ARP100104564A AR079349A1 (es) 2009-12-10 2010-12-10 Anticuerpos neutralizadores contra el receptor de prolactina y su uso terapeutico
ARP100104707A AR079641A1 (es) 2009-12-10 2010-12-17 Compuestos para el diagnostico por imagenes de la muerte de las celulas por apotosis

Family Applications Before (3)

Application Number Title Priority Date Filing Date
ARP100104563A AR079348A1 (es) 2009-12-10 2010-12-10 Anticuerpos neutralizadores contra el receptor de prolactina y su uso terapeutico
ARP100104566A AR079351A1 (es) 2009-12-10 2010-12-10 Anticuerpos neutralizadores contra el receptor de prolactina y su uso terapeutico
ARP100104565A AR079350A1 (es) 2009-12-10 2010-12-10 Anticuerpos neutralizadores contra el receptor de prolactina y su uso terapeutico

Family Applications After (2)

Application Number Title Priority Date Filing Date
ARP100104564A AR079349A1 (es) 2009-12-10 2010-12-10 Anticuerpos neutralizadores contra el receptor de prolactina y su uso terapeutico
ARP100104707A AR079641A1 (es) 2009-12-10 2010-12-17 Compuestos para el diagnostico por imagenes de la muerte de las celulas por apotosis

Country Status (40)

Country Link
US (6) US20120315276A1 (es)
EP (13) EP2332995A1 (es)
JP (7) JP2013513559A (es)
KR (2) KR101765968B1 (es)
CN (6) CN102741291A (es)
AP (1) AP2012006343A0 (es)
AR (6) AR079348A1 (es)
AU (2) AU2010330165B2 (es)
BR (2) BR112012014048B1 (es)
CA (6) CA2783654A1 (es)
CL (2) CL2012001540A1 (es)
CR (2) CR20120312A (es)
CU (2) CU23973B1 (es)
CY (2) CY1118209T1 (es)
DK (2) DK2510002T3 (es)
DO (2) DOP2012000159A (es)
EA (2) EA029327B1 (es)
EC (2) ECSP12011966A (es)
ES (2) ES2603352T3 (es)
GT (1) GT201200186A (es)
HK (2) HK1180354A1 (es)
HR (2) HRP20161401T1 (es)
HU (2) HUE031631T2 (es)
IL (2) IL220149A (es)
IN (2) IN2012DN05078A (es)
LT (2) LT2510002T (es)
MA (1) MA33888B1 (es)
ME (1) ME02577B (es)
MX (2) MX2012006621A (es)
NZ (2) NZ600512A (es)
PE (3) PE20121561A1 (es)
PL (2) PL2510002T3 (es)
PT (2) PT2510002T (es)
RS (2) RS55589B1 (es)
SG (2) SG181513A1 (es)
SI (2) SI2510006T1 (es)
TN (1) TN2012000294A1 (es)
TW (5) TWI487536B (es)
WO (6) WO2011069797A1 (es)
ZA (2) ZA201204213B (es)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2332995A1 (en) * 2009-12-10 2011-06-15 Bayer Schering Pharma Aktiengesellschaft Neutralizing prolactin receptor antibodies and their therapeutic use
SG10201502587SA (en) 2010-03-01 2015-06-29 Bayer Healthcare Llc Optimized monoclonal antibodies against tissue factor pathway inhibitor (tfpi)
EP2530089A1 (en) * 2011-06-03 2012-12-05 Bayer Pharma Aktiengesellschaft Neutralising prolactin receptor antibody Mat3 and its therapeutical use
CN104302664B (zh) 2012-03-14 2021-11-26 瑞泽恩制药公司 多特异性抗原结合分子及其用途
US9592297B2 (en) * 2012-08-31 2017-03-14 Bayer Healthcare Llc Antibody and protein formulations
US8883979B2 (en) * 2012-08-31 2014-11-11 Bayer Healthcare Llc Anti-prolactin receptor antibody formulations
BR112015015289A2 (pt) * 2012-12-24 2017-08-15 Abbvie Inc Proteínas que se ligam ao receptor de prolactina e usos das mesmas
CA2906101A1 (en) * 2013-03-15 2014-09-18 Bayer Healthcare Llc Anti-prolactin receptor antibody formulations
TWI641620B (zh) 2013-08-21 2018-11-21 再生元醫藥公司 抗－ｐｒｌｒ抗體及其用途
US9545451B2 (en) 2013-08-21 2017-01-17 Regeneron Pharmaceuticals, Inc. Anti-PRLR antibodies and methods for killing PRLR-expressing cells
US10308697B2 (en) 2014-04-30 2019-06-04 President And Fellows Of Harvard College Fusion proteins for treating cancer and related methods
CN106999587B (zh) 2014-10-02 2023-09-29 希望之城公司 多价中间表位，中间表位结合抗体及其用途
WO2016121908A1 (ja) * 2015-01-30 2016-08-04 学校法人埼玉医科大学 抗ａｌｋ２抗体
KR20180025865A (ko) 2015-07-06 2018-03-09 리제너론 파마슈티칼스 인코포레이티드 다중특이적 항원 결합 분자 및 이의 용도
US11352446B2 (en) 2016-04-28 2022-06-07 Regeneron Pharmaceuticals, Inc. Methods of making multispecific antigen-binding molecules
CA3044534A1 (en) 2016-11-29 2018-06-07 Regeneron Pharmaceuticals, Inc. Methods of treating prlr positive breast cancer
FR3062213B1 (fr) * 2017-01-20 2021-02-26 Endodiag Utilisation du recepteur cd71 dans la detection et le traitement de l’endometriose
TW201836647A (zh) 2017-04-06 2018-10-16 美商艾伯維有限公司 抗－ｐｒｌｒ抗體藥物軛合物（ａｄｃ）及其用途
CN110785169A (zh) * 2017-05-12 2020-02-11 千年制药公司 用三氮杂螺[4.5]癸酮治疗胃轻瘫
US20210128728A1 (en) 2017-07-10 2021-05-06 Bayer Pharma Aktiengesellschaft Prolactin receptor antibody for male and female pattern hair loss
EP3749373A1 (en) 2018-02-07 2020-12-16 Regeneron Pharmaceuticals, Inc. Methods and compositions for therapeutic protein delivery
WO2019169330A1 (en) * 2018-03-02 2019-09-06 Oncolix, Inc. Method for treating cancers expressing prolactin receptor
CN109627340B (zh) * 2018-12-05 2021-02-12 上海交通大学 Cd3和prlr双特异性抗体及其构建与应用
US10467487B1 (en) * 2018-12-11 2019-11-05 Chongqing Jinkang New Energy Automobile Co., Ltd. Fusion-based traffic light recognition for autonomous driving
CN112425568A (zh) * 2020-12-11 2021-03-02 上海市计划生育科学研究所 一种建立具有emt特征的良性前列腺增生bph犬模型的方法
UY39610A (es) 2021-01-20 2022-08-31 Abbvie Inc Conjugados anticuerpo-fármaco anti-egfr
CN114853890B (zh) * 2022-03-16 2023-04-28 沈阳三生制药有限责任公司 一种prlr抗原结合蛋白及其制备方法和应用
CN114634574B (zh) * 2022-04-18 2022-12-20 先进生物(苏州)有限公司 抗B7H6的scFv抗体、其编码基因及其应用
CN117285625B (zh) * 2023-11-24 2024-01-23 南京佰抗生物科技有限公司 抗泌乳素蛋白的单克隆抗体及应用

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4657760A (en) 1979-03-20 1987-04-14 Ortho Pharmaceutical Corporation Methods and compositions using monoclonal antibody to human T cells
US4634665A (en) 1980-02-25 1987-01-06 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US5179017A (en) 1980-02-25 1993-01-12 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4510245A (en) 1982-11-18 1985-04-09 Chiron Corporation Adenovirus promoter system
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5168062A (en) 1985-01-30 1992-12-01 University Of Iowa Research Foundation Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
US5206344A (en) 1985-06-26 1993-04-27 Cetus Oncology Corporation Interleukin-2 muteins and polymer conjugation thereof
US4968615A (en) 1985-12-18 1990-11-06 Ciba-Geigy Corporation Deoxyribonucleic acid segment from a virus
US4986615A (en) 1988-10-17 1991-01-22 The Vendo Company Vending apparatus
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5225212A (en) 1989-10-20 1993-07-06 Liposome Technology, Inc. Microreservoir liposome composition and method
GB9105245D0 (en) * 1991-03-12 1991-04-24 Lynxvale Ltd Binding molecules
ES2202310T3 (es) 1991-12-13 2004-04-01 Xoma Corporation Metodos y materiales para la preparacion de dominios variables de anticuerpos modificados y sus usos terapeuticos.
EP0859841B1 (en) 1995-08-18 2002-06-19 MorphoSys AG Protein/(poly)peptide libraries
JP2001500865A (ja) * 1996-09-13 2001-01-23 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティ 避妊の非ホルモン法
GB9701425D0 (en) 1997-01-24 1997-03-12 Bioinvent Int Ab A method for in vitro molecular evolution of protein function
US6867187B2 (en) * 2000-12-22 2005-03-15 Trustees Of The University Of Pennsylvania Composition and method for modulating somatolactogenic function
EP1325930A1 (en) * 2002-01-08 2003-07-09 Institut National De La Sante Et De La Recherche Medicale (Inserm) Mammal prolactin variants
AU2003300904A1 (en) * 2002-12-13 2004-07-09 The Ohio State University Antagonists for human prolactin
GB0305790D0 (en) * 2003-03-13 2003-04-16 Glaxosmithkline Biolog Sa Novel Composition
WO2006046689A1 (ja) * 2004-10-28 2006-05-04 Kyowa Hakko Kogyo Co., Ltd. 子宮内膜症治療剤
WO2006089678A2 (en) * 2005-02-22 2006-08-31 Bioinvent International Ab Antibodies and peptides binding to hiv tat, and uses thereof
GB0517878D0 (en) * 2005-09-02 2005-10-12 Bioinvent Int Ab Immunotherapeutic treatment
US7422899B2 (en) 2005-10-05 2008-09-09 Biogen Idec Ma Inc. Antibodies to the human prolactin receptor
GEP20125612B (en) * 2006-08-18 2012-08-27 Novartis Ag Prlr-specific antibody and usage thereof
AU2008278704A1 (en) 2007-05-30 2009-01-29 Auckland Uniservices Limited Antibodies and sirna against growth hormone, prolactin and proliferin for use in the treatment of tumors and endometriosis
EP2025683A1 (en) * 2007-08-13 2009-02-18 INSERM (Institut National de la Santé et de la Recherche Medicale) Variants of prolactin as antagonists of its receptor
EP2332995A1 (en) * 2009-12-10 2011-06-15 Bayer Schering Pharma Aktiengesellschaft Neutralizing prolactin receptor antibodies and their therapeutic use
WO2011139375A1 (en) * 2010-05-06 2011-11-10 Ludwig Institute For Cancer Research Ltd Antibodies directed against carbonic anhydrase ix and methods and uses thereof
GB201020995D0 (en) * 2010-12-10 2011-01-26 Bioinvent Int Ab Biological materials and uses thereof

Also Published As

Publication number Publication date
JP6199930B2 (ja) 2017-09-20
SI2510002T1 (sl) 2016-12-30
MX2012006621A (es) 2012-10-05
TW201130507A (en) 2011-09-16
SG181511A1 (en) 2012-07-30
TW201138817A (en) 2011-11-16
MA33888B1 (fr) 2013-01-02
SG181513A1 (en) 2012-07-30
AR079350A1 (es) 2012-01-18
AR079349A1 (es) 2012-01-18
US20130022606A1 (en) 2013-01-24
US9649374B2 (en) 2017-05-16
WO2011069795A4 (en) 2011-08-18
TN2012000294A1 (en) 2013-12-12
AU2010330161A1 (en) 2012-07-05
PE20121561A1 (es) 2012-11-25
WO2011069794A1 (en) 2011-06-16
ZA201204213B (en) 2014-08-27
EP2510002A1 (en) 2012-10-17
HUE031631T2 (en) 2017-07-28
DOP2012000160A (es) 2012-09-30
BR112012015852B8 (pt) 2021-05-25
IN2012DN05078A (es) 2015-10-23
IN2012DN05082A (es) 2015-10-09
JP2013513361A (ja) 2013-04-22
JP2013513365A (ja) 2013-04-22
GT201200186A (es) 2014-01-06
WO2011069795A1 (en) 2011-06-16
US20120315276A1 (en) 2012-12-13
EP2567979A1 (en) 2013-03-13
AR079351A1 (es) 2012-01-18
CA2783610C (en) 2018-10-30
EP2570436A1 (en) 2013-03-20
CA2783678A1 (en) 2011-06-16
AU2010330165A1 (en) 2012-07-19
MX2012006620A (es) 2012-06-21
NZ600511A (en) 2014-01-31
CA2783654A1 (en) 2011-06-16
PL2510002T3 (pl) 2017-02-28
US9241989B2 (en) 2016-01-26
ES2603352T3 (es) 2017-02-27
PT2510002T (pt) 2016-11-23
MX339343B (es) 2016-05-20
KR20120112528A (ko) 2012-10-11
TW201130505A (en) 2011-09-16
CL2012001539A1 (es) 2012-10-12
LT2510006T (lt) 2016-12-12
HK1180700A1 (en) 2013-10-25
EA028678B1 (ru) 2017-12-29
EP2510003A1 (en) 2012-10-17
CR20120312A (es) 2012-08-27
ES2610654T3 (es) 2017-04-28
AR079641A1 (es) 2012-02-08
BR112012015852B1 (pt) 2020-12-29
TWI508744B (zh) 2015-11-21
BR112012014048A2 (pt) 2017-10-31
WO2011069797A1 (en) 2011-06-16
JP6066474B2 (ja) 2017-01-25
TW201130504A (en) 2011-09-16
CN102884082A (zh) 2013-01-16
JP2013513559A (ja) 2013-04-22
CR20120310A (es) 2012-08-01
IL220149A (en) 2017-09-28
DK2510006T3 (en) 2017-01-23
CN102858803A (zh) 2013-01-02
PL2510006T3 (pl) 2017-06-30
CU20120092A7 (es) 2012-10-15
KR101765968B1 (ko) 2017-08-08
BR112012015852A8 (pt) 2017-06-27
HRP20170016T1 (hr) 2017-02-24
CN102741291A (zh) 2012-10-17
JP2013513362A (ja) 2013-04-22
JP2013513363A (ja) 2013-04-22
CY1118407T1 (el) 2017-06-28
DOP2012000159A (es) 2012-09-30
CA2783513A1 (en) 2011-06-16
TW201130506A (en) 2011-09-16
HUE030143T2 (en) 2017-04-28
BR112012015852A2 (pt) 2017-05-23
CA2783651A1 (en) 2011-06-16
HRP20161401T1 (hr) 2016-12-16
AU2010330165B2 (en) 2015-07-16
CA2783514A1 (en) 2011-06-16
EP2510006A1 (en) 2012-10-17
EP2567977A1 (en) 2013-03-13
JP2015180690A (ja) 2015-10-15
TWI487536B (zh) 2015-06-11
KR101790366B1 (ko) 2017-10-26
WO2011069796A1 (en) 2011-06-16
KR20120112527A (ko) 2012-10-11
CY1118209T1 (el) 2017-06-28
EP2567980A1 (en) 2013-03-13
US20130171147A1 (en) 2013-07-04
CL2012001540A1 (es) 2013-01-18
EP2510002B1 (en) 2016-08-24
ECSP12011965A (es) 2012-07-31
EP2510006B1 (en) 2016-11-09
CN102858804A (zh) 2013-01-02
DK2510002T3 (en) 2016-11-28
ZA201204214B (en) 2014-08-27
CA2783610A1 (en) 2011-06-16
WO2011069798A1 (en) 2011-06-16
IL220149A0 (en) 2012-07-31
IL220151A0 (en) 2012-07-31
RS55277B1 (sr) 2017-02-28
EP2510005A1 (en) 2012-10-17
EA201200860A1 (ru) 2013-01-30
EP2332995A1 (en) 2011-06-15
EP2510004A1 (en) 2012-10-17
HK1180354A1 (en) 2013-10-18
EA201200851A1 (ru) 2013-01-30
CU20120093A7 (es) 2012-10-15
CA2783513C (en) 2018-08-14
NZ600512A (en) 2014-11-28
EP2567978A1 (en) 2013-03-13
PE20171134A1 (es) 2017-08-09
CN102884082B (zh) 2015-05-20
WO2011069799A1 (en) 2011-06-16
AR079348A1 (es) 2012-01-18
EP2570435A1 (en) 2013-03-20
AP2012006343A0 (en) 2012-06-30
CN102858801A (zh) 2013-01-02
SI2510006T1 (sl) 2017-02-28
LT2510002T (lt) 2016-11-25
ME02577B (me) 2017-06-20
US20120321632A1 (en) 2012-12-20
PE20121360A1 (es) 2012-10-11
EP2510007A1 (en) 2012-10-17
US20130129739A1 (en) 2013-05-23
CN102947338A (zh) 2013-02-27
JP2013513364A (ja) 2013-04-22
US20130272968A1 (en) 2013-10-17
AU2010330161B2 (en) 2015-07-09
EA029327B1 (ru) 2018-03-30
PT2510006T (pt) 2017-01-20
CN102947338B (zh) 2015-11-25
CU23973B1 (es) 2013-12-27
BR112012014048B1 (pt) 2021-10-26
ECSP12011966A (es) 2012-07-31
RS55589B1 (sr) 2017-06-30

Similar Documents

Publication Publication Date Title
AR079352A1 (es) Anticuerpos neutralizadores contra el receptor de prolactina y su uso terapeutico
CU20130163A7 (es) El anticuerpo neutralizador del receptor de prolactina mat3 y su uso terapéutico
MX2019000586A (es) Virus adenoasociados (aav) sflt-1 para usarse en el tratamiento de degeneración macular relacionada con la edad (amd).
EA201391154A2 (ru) Способы и композиции для нацеливания на адипоциты у млекопитающих
EA201791361A1 (ru) Терапия антагонистом рецепторов окситоцина в лютеиновую фазу для имплантации и беременности у женщин, проходящих процедуры вспомогательных репродуктивных технологий
EA201491614A1 (ru) Способ лечения гинекологических заболеваний
EA201990106A1 (ru) Режим приема селективного модулятора рецептора прогестерона (sprm)
CL2011001034A1 (es) Compuestos derivados de pirrolidina; compuestos intermediarios; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como endometriosis, fibroides uterinos, menorragia, entre otras.
EA201590903A1 (ru) Применение и режим приема фармацевтической композиции, содержащей левоноргестрел и ингибитор цог, для контрацепции по мере необходимости ("on-demand")
RU2009123421A (ru) Способ применения наноформы транс-резвератрола для лечения и профилактики гормонозависимых пролиферативных процессов, в том числе опухолей

Legal Events

Date Code Title Description
FG Grant, registration